PharmExec Direct eNewsletter

PharmExec Direct:
Having trouble viewing this e-mail? Click here.

You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile

PharmExec Direct | From the editors of Pharmaceutical Executive

September 2, 2010 | ISSUE NUMBER 164 VOL 8

M&A
Genzyme Snubs Sanofi Offer
Sanofi offered $18.5 billion to acquire Genzyme, but it doesn’t appear to be enough for it to get into bed with the genetic disease drug manufacturer.

Warning Letter
Baxter Receives Third FDA Warning for Misleading Promotional Material
FDA letter to Baxter International over claims about its lung drug is company’s third warning for violative promotion in just over two years.

Deals
Pfizer Adds FoldRx to its Specialty Care Unit
The drug giant nabbed protein-folding drug firm FoldRx to help bolster its specialty care division that focuses on orphan and rare diseases.

New & Noteworthy
Adherence Through Education
Pharma’s quest for patient adherence has been trying. Could better patient education be the answer?

// EUSA Pharma appointed Stephen A. Stamp to its board of directors. // Former Singapore EDB Officer, Chew Hwee Yong, joined Menicon as chief of special projects. // Hill-Rom appointed Scott Jeffers as senior vice president, global supply chain. // Oncothyreon appointed Julie M. Eastland chief financial officer. // Millennium Laboratories named David Cohen chief operating officer. // PrimeraDx named Matthew F. McManus president and CEO. //

Release Higher Performance Through Business Analytics
Wednesday, Sept. 22, 11 A.M. Eastern; 8 A.M. Pacific
Register Free at http://pharmexec.com/analytics

3-D Segmentation: Managing your Brand’s Three Most Important Influencers
Thursday, Oct. 7, at 12 P.M. Eastern; 9 A.M. Pacific
Register Free at http://pharmexec.com/geo

Sep 9–10 Clinical Trials in Latin America
Lima, Peru

Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC

Dec 8—9 CMAC 2010 - Commercialization and Market Access Congress
Orlando, FL

A year and a half into President Obama’s tenure, how do you view the effectiveness of the “new” FDA?

Roche’s $1 Billion Bet on Stapled Peptides

More J&J Quality Problems Revealed with New Recall

Has Pandora’s Box Opened?

Sanofi’s Courtship of Genzyme in Limbo


	Follow Pharm Exec on Twitter
	Follow Pharm Exec on Facebook

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.